Paratek Pharmaceuticals, Inc.
75 Park Plaza
About Paratek Pharmaceuticals, Inc.Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria.
Omadacycline is a new once-daily oral and IV, well-tolerated broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.
Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily, oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan initiated two identical Phase 3 registration studies in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris. Top line data are expected in the first half of 2017.
Board of Directors Michael F. Bigham Chairman of the Board and Chief Executive Officer
Evan Loh, MD Director and President, Chief Medical Officer
Thomas J. Dietz, Ph.D. Director
Timothy Franson, M.D., Director
Richard Lim Director
Kristine Peterson Director
Robert Radie Director
Jeffrey Stein, Ph.D. Director
Last Updated: 04-23-02
114 articles with Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., Novartis AG (JOBS) Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Trial Paratek Pharmaceuticals, Inc. Antibiotics Help Against "Superbug", University of Virginia Study
Paratek Pharmaceuticals, Inc. Reports Positive Phase 2 Clinical Data on its New Antibiotic PTK 0796 in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Paratek Pharmaceuticals, Inc. to Present Clinical Data in Late Breaker Presentation at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Paratek Pharmaceuticals, Inc. Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
Warner Chilcott and Paratek Pharmaceuticals, Inc. Sign Collaboration Agreement for Novel, Narrow-Spectrum Agents for Acne and Rosacea
Families Of Spinal Muscular Atrophy and Paratek Pharmaceuticals, Inc. Expand Drug Discovery Collaboration for Spinal Muscular Atrophy
Paratek Pharmaceuticals, Inc. Presents New Preclinical Data On Novel Aminomethylcycline Antibiotic MK-2764 At 46th Annual ICAAC
Biotechnology Industry Organization (BIO) Release: Biotech CEO To Testify Before Senate Small Business Committee
Families Of Spinal Muscular Atrophy And Paratek Pharmaceuticals, Inc. Announce Drug Discovery Collaboration For Spinal Muscular Atrophy
Merck & Co., Inc. And Paratek Pharmaceuticals, Inc. Sign Collaboration Agreement For Novel Antibiotic PTK 0796 Currently In Phase 1 Testing